Meta Analysis Of Clinical Application And Safety Evaluation Of SGLT2 Inhibitors

Objective: Study sodium-glucose cooperative transporter 2(SGLT2)inhibitors in the treatment of type 2 diabetes(T2DM)The clinical efficacy and safety of patients with chronic renal insufficiency(CKD)are systematically evaluated.Methods: through keyword search,a SGLT2 Randomized Clinical Trials(RCTs)study was conducted in a certain period of time for the treatment of type 2 diabetic patients with chronic kidney disease.The search range was Pub Med,Embase,How Net and VIP related databases.The retrieval date is up to December 30,2020.According to the inclusion and exclusion criteria,the references are selected,the quality of the references is evaluated and the materials are obtained.The system software Stata 15.0 completes the meta-analysis.Results: Nine randomized controlled trials that met the requirements were finally determined,involving nearly 10,000 patients.Meta-analysis of these data showed that for these patients,SGLT2 inhibitors achieved good therapeutic effects.The results of the study showed SGLT2 inhibitors significantly reduce glycosylated hemoglobin,fasting plasma glucose(FPG),body weight(BW),systolic blood pressure(SBP),diastolic blood pressure(DBP),and estimated Glomerular Filtration Rate,e GFR),but at the same time,blood urea nitrogen(BUN)and blood creatinine(Cr)and other indicators for evaluating renal function have a slight increase;it also increases the incidence of reproductive tract infections,but for the total The incidence of adverse events and all-cause mortality have been significantly reduced,and will not affect the incidence of hypoglycemia and urinary tract infectionrelated side effects.The results of comparative analysis of subgroups showed that the effect of SGLT2 inhibitors was reduced to a certain extent when renal function developed to stage3 of chronic renal insufficiency;the renal function of patients was basically preserved after the treatment time was prolonged;patients with stage 3 of chronic renal insufficiency received this drug After intervention,the incidence of reproductive tract infections has increased,and the risk of various adverse reactions has increased and whether there is a correlation between the staging of chronic renal insufficiency has not been studied in depth.Conclusion: SGLT2 inhibitors can relieve various clinical symptoms of ckd2 patients with high safety;However,the treatment effect of ckd3 patients decreased,and the proportion of adverse events such as reproductive tract infection increased.However,with the extension of treatment,the renal function tended to be retained;For patients with ckd4 or ESRD,the relevant data are missing,and the effect can not be accurately judged.In the future,we should increase the sample size to further study the therapeutic effect of SGLT2 inhibitors on such patients,so as to provide support for its application.